Boaz v. Boyle & Co.

40 Cal. App. 4th 700, 46 Cal. Rptr. 2d 888, 95 Daily Journal DAR 15482, 95 Cal. Daily Op. Serv. 8923, 1995 Cal. App. LEXIS 1131
CourtCalifornia Court of Appeal
DecidedNovember 21, 1995
DocketB076776
StatusPublished
Cited by26 cases

This text of 40 Cal. App. 4th 700 (Boaz v. Boyle & Co.) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Boaz v. Boyle & Co., 40 Cal. App. 4th 700, 46 Cal. Rptr. 2d 888, 95 Daily Journal DAR 15482, 95 Cal. Daily Op. Serv. 8923, 1995 Cal. App. LEXIS 1131 (Cal. Ct. App. 1995).

Opinion

Opinion

EPSTEIN, J.

The grandmothers of the plaintiff-appellants in this case ingested the drug diethylstilbestrol (DES) while pregnant with appellants’ mothers. It is claimed that, as a result of the ingestion, appellants’ mothers suffered disabilities that manifested themselves at various points after birth and that their children (appellants) suffered similar injuries when they were bom. All but one of the appellants is a resident of the state of New York or New Jersey. The DES ingestion occurred in the state of New York. All of them pursued actions against defendant-respondents in that state. Each of the respondents manufactured DES during the period of the grandmothers’ ingestion, and all but one does business in California. Only one appellant is domiciled in this state. New York State declined to recognize the preconception tort proffered by appellants. Having failed to succeed in New York, appellants sought relief in California.

The trial court dismissed the actions of the nonresident appellants under the doctrine forum non conveniens. (The action of the California appellant, Lara Ameen, was not dismissed.) We shall affirm the orders of dismissal. We do so because the only basis for bringing the actions in this state is the prospect that the law in California is more hospitable to their claims than the law of New York. We follow the decision in Shiley Inc. v. Superior Court (1992) 4 Cal.App.4th 126 [6 Cal.Rptr.2d 38], in holding that this circumstance is not sufficient to compel a California court to entertain the nonresident appellants’ suit.

One of the defendant-respondents, Emons Industries, Inc., does not do business in California. It sold DES during the period appellants’ grandmothers ingested it, but its activities never subjected it to the general jurisdiction of this state. There is a basis to conclude that it is subject to special jurisdiction because of sales it made to physicians here during the relevant *705 period. But we agree with the trial court that there is no justification in the record for an assertion of jurisdiction on that account by any of the appellants because there is no showing or claim that Emons’s activities in this state contributed to the injuries suffered by any of the appellants before us on this appeal.

We conclude, therefore, that the trial court did not err, and we affirm its orders.

Factual and Procedural Summary

DES is a synthetic estrogen compound, developed and marketed for the purpose of preventing miscarriage. It caused cancerous growths in many of the women who ingested it, and caused cancer and other disease to their children as a result of the in útero exposure. The tragic history of this drug, and the trail of injuries it has caused, is outlined in Sindell v. Abbott Laboratories (1980) 26 Cal.3d 588, 594 [163 Cal.Rptr. 132, 607 P.2d 924, 2 A.L.R.4th 171], Bichler v. Eli Lilly & Co. (1982) 55 N.Y.2d 571 [450 N.Y.S.2d 116, 436 N.E.2d 182, 22 A.L.R.4th 171], In re DES Cases (E.D.N.Y 1992) 789 F.Supp. 552, and other places. We take it as established for purposes of the forum non conveniens and jurisdictional motions before the trial court, and here, that appellants’ grandmothers ingested the drug while pregnant with appellants’ mothers, and that their doing so ultimately manifested itself in injuries to appellants. We also assume that each of the respondents manufactured and sold DES during the 30-year period (1941-1971) that it was on the market.

The respondents were sued in New York, where each of them does business and is subject to the general jurisdiction of the state courts. Motions were brought challenging the viability of their causes of action, depending as they did on preconception torts. That is a theory generally rejected in New York. (Albala v. City of New York (1981) 54 N.Y.2d 269 [445 N.Y.S.2d 108, 429 N.E.2d 786].) All but one of the appellants were bom in New York or New Jersey and are residents of one of those states. The exception, Lara Ameen, was bom in California and is now a resident of this state. The New York trial court mled for respondents, the intermediate court reversed, and the New York Court of Appeals—the highest court of that state—finally settled the issue. Framing the question as “whether the liability of manufacturers of [DES] should extend to a so-called ‘third generation’ plaintiff, the granddaughter of a woman who ingested the drug,” the court answered in the negative and affirmed the trial court’s grant of summary judgment in favor of the manufacturers. (Enright v. Eli Lilly & Co. (1991) 77 N.Y.2d 377 [568 N.Y.S.2d 550, 570 N.E.2d 198, 199]; cert. den., 502 U.S. 868 [116 L.Ed.2d 157, 112 S.Ct. 197].)

*706 The appellants then filed actions against the same respondents in California. Respondent Eli Lilly & Co. moved to dismiss on forum non conveniens grounds. Each of the appellants other than Ms. Ameen, and all of the respondents, agreed to be bound (at the trial court level) by the ruling in the case of appellant Boaz. The trial court ruled that New York is a suitable, alternative forum, and that the balance of private and public factors did not favor retaining the action for trial in California. The case of each appellant— other than Ms. Ameen—was dismissed on forum non conveniens grounds. Insofar as the record shows, Ms. Ameen’s case is proceeding against each of the respondents other than Emons. Emons moved separately to quash service and dismiss for lack of jurisdiction as to all of the appellants, including Ms. Ameen. Its motion was granted. The parties have agreed that applicability of the forum non conveniens doctrine shall be based on the factual and procedural history in the New York Enright decision.

A timely notice of appeal was filed on behalf of each of the appellants. The orders are appealable. (Code Civ. Proc., § 904.1, subd. (a)(3); all further statutory citations are to that code.) We granted a motion to consolidate the appeals, 1 and we now affirm.

Discussion

I

Forum Non Conveniens

“Obviously, the proposition that a court having jurisdiction must exercise it, is not universally true.” (Brandeis, J., in Canada Malting Co., Ltd. v. Paterson Steamships, Ltd. (1932) 285 U.S. 413, 422 [76 L.Ed. 837, 842, 52 S.Ct. 413].) A principal reason for not exercising jurisdiction, recognized by state and federal courts, is that the forum is not convenient. This doctrine, Latinized in the rubric “forum non conveniens,” has a long history. (See Piper Aircraft Co. v. Reyno (1981) 454 U.S. 235, 248, fn. 13 [70 L.Ed.2d 419, 431, 102 S.Ct. 252].) It was crystallized by our national court in Gulf Oil Corp. v. Gilbert

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Seryani v. American University of Madaba CA4/2
California Court of Appeal, 2025
Hardell v. Vanzyl
California Court of Appeal, 2024
Amyris v. Lavvan CA1/2
California Court of Appeal, 2023
Almeida v. Olympusat CA2/1
California Court of Appeal, 2021
Wang v. Fang
California Court of Appeal, 2021
Bristol-Myers Squibb Co. v. Superior Court of San Francisco County
377 P.3d 874 (California Supreme Court, 2016)
Wonderworks Pte. v. Hewlett-Packard CA6
California Court of Appeal, 2016
Delaware North Co. v. Superior Court CA2/3
California Court of Appeal, 2016
Klotz v. Ezzes CA2/1
California Court of Appeal, 2015
Aghaian v. Minassian
234 Cal. App. 4th 427 (California Court of Appeal, 2015)
Bristol-Myers Squibb v. Super. Ct.
California Court of Appeal, 2014
National Football League v. Fireman's Fund Insurance
216 Cal. App. 4th 902 (California Court of Appeal, 2013)
Investors Equity Life Holding Co. v. Schmidt
195 Cal. App. 4th 1519 (California Court of Appeal, 2011)
Hahn v. Diaz-Barba
194 Cal. App. 4th 1177 (California Court of Appeal, 2011)
Guimei v. General Electric Co.
172 Cal. App. 4th 689 (California Court of Appeal, 2009)
Cadle Co. II, Inc. v. Fiscus
163 Cal. App. 4th 1232 (California Court of Appeal, 2008)
Paneno v. Centres for Academic Programmes Abroad Ltd.
13 Cal. Rptr. 3d 759 (California Court of Appeal, 2004)
American Cemwood Corp. v. American Home Assurance Co.
104 Cal. Rptr. 2d 670 (California Court of Appeal, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
40 Cal. App. 4th 700, 46 Cal. Rptr. 2d 888, 95 Daily Journal DAR 15482, 95 Cal. Daily Op. Serv. 8923, 1995 Cal. App. LEXIS 1131, Counsel Stack Legal Research, https://law.counselstack.com/opinion/boaz-v-boyle-co-calctapp-1995.